ALX Oncology GAAP EPS of -$0.49 misses by $0.04

2 hours ago 1

ALX Oncology press release (NASDAQ:ALXO): Q2 GAAP EPS of -$0.49 misses by $0.04.
Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of June 30, 2025, were $83.5 million. The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations into Q1 of 2027.

Recommended For You